MoonLake Immunotherapeutics (MLTX)
39.74
-1.12
(-2.74%)
USD |
NASDAQ |
May 17, 16:00
39.74
0.00 (0.00%)
After-Hours: 20:00
MoonLake Immunotherapeutics SG&A Expense (Quarterly): 6.806M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.806M |
| December 31, 2023 | 6.931M |
| September 30, 2023 | 5.392M |
| June 30, 2023 | 4.482M |
| March 31, 2023 | 5.516M |
| December 31, 2022 | 5.327M |
| Date | Value |
|---|---|
| September 30, 2022 | 5.746M |
| June 30, 2022 | 6.252M |
| March 31, 2022 | 5.487M |
| September 30, 2021 | 5.598M |
| June 30, 2021 | 2.815M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.815M
Minimum
Jun 2021
6.931M
Maximum
Dec 2023
5.487M
Average
5.516M
Median
Mar 2023
SG&A Expense (Quarterly) Benchmarks
| Qiagen NV | 138.69M |
| LENZ Therapeutics Inc | 5.551M |
| AC Immune SA | 5.688M |
| CRISPR Therapeutics AG | 17.95M |
| Addex Therapeutics Ltd | 1.922M |